Searching journal content for somatostatin analogue (as phrase) in full text.

Displaying results 1-10 of 106
For checked items
  1. Thematic Review:
    • Hermine Mohr and
    • Natalia S Pellegata
    Animal models of MEN1 Endocr Relat Cancer 24 (10) T161-T177, doi:10.1530/ERC-17-0249 first published on 25 July 2017
    ...somatostatin analogue ~~~
  2. Research:
    • Massimo Terzolo,
    • Giuseppe Reimondo,
    • Paola Berchialla,
    • Emanuele Ferrante,
    • Elena Malchiodi,
    • Laura De Marinis,
    • Rosario Pivonello,
    • Silvia Grottoli,
    • Marco Losa,
    • Salvatore Cannavo,
    • Diego Ferone,
    • Marcella Montini,
    • Marta Bondanelli,
    • Ernesto De Menis,
    • Chiara Martini,
    • Efisio Puxeddu,
    • Antonino Velardo,
    • Alessandro Peri,
    • Marco Faustini-Fustini,
    • Patrizia Tita,
    • Francesca Pigliaru,
    • Giulia Peraga,
    • Giorgio Borretta,
    • Carla Scaroni,
    • Nicoletta Bazzoni,
    • Antonio Bianchi,
    • Alessandro Berton,
    • Andreea Liliana Serban,
    • Roberto Baldelli,
    • Letizia Maria Fatti,
    • Annamaria Colao,
    • Maura Arosio,
    • and for the Italian Study Group of Acromegaly
    Acromegaly is associated with increased cancer risk: a survey in Italy Endocr Relat Cancer 24 (9) 495-504, doi:10.1530/ERC-16-0553 first published on 14 July 2017
    ...somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study. European Journal of Endocrinology 169 367–376. (doi:10.1530/EJE-13-0166) Boguszewski CL & Ayuk J 2016 Acromegaly and cancer risk: an old debate revisited. European Journal ~~~
  3. Review:
    • Wouter T Zandee,
    • Kimberly Kamp,
    • Roxanne C van Adrichem,
    • Richard A Feelders,
    • and Wouter W de Herder
    Effect of hormone secretory syndromes on neuroendocrine tumor prognosis Endocr Relat Cancer 24 (7) R261-R274, doi:10.1530/ERC-16-0538 first published on 8 May 2017
    ...somatostatin analogue . New England Journal of Medicine 315 663 – 666 . ( doi:10.1056/NEJM198609113151102 ) ↵ Kwekkeboom DJ , de Herder WW , Kam BL , van Eijck CH , van Essen M , Kooij PP , Feelders RA , van Aken MO & Krenning EP 2008 Treatment with the radiolabeled somatostatin analog [177 Lu-D ~~~
  4. Review:
    • David A Pattison and
    • Rodney J Hicks
    Molecular imaging in the investigation of hypoglycaemic syndromes and their management Endocr Relat Cancer 24 (6) R203-R221, doi:10.1530/ERC-17-0005 first published on 11 April 2017
    ...somatostatin analogue 111In-DTPA-octreotide was developed at the Erasmus Medical Centre in the Netherlands for imaging NETs in 1989 (Lamberts  et  al. 1990). More recently, radiolabelling of octreotide with the gamma emitter 111In has been largely superseded by the positron emitter 68Ga labelled to ~~~
  5. Review:
    • Maria Chiara Zatelli,
    • Erika Maria Grossrubatscher,
    • Elia Guadagno,
    • Concetta Sciammarella,
    • Antongiulio Faggiano,
    • and Annamaria Colao
    Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms Endocr Relat Cancer 24 (6) R223-R237, doi:10.1530/ERC-17-0091 first published on 7 April 2017
    ...somatostatin analogue (circulating tumor cells in Somatuline Autogel-treated neuroendocrine tumors patients (CALM-NET); ClinicalTrials.gov Identifier: NCT02075606). In addition, the employed dynamic approach ovomes the limit of applying a single CTC threshold level, as in previous studies performed ~~~
  6. Review:
    • Anna Angelousi,
    • Georgios K Dimitriadis,
    • Georgios Zografos,
    • Svenja Nölting,
    • Gregory Kaltsas,
    • and Ashley Grossman
    Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies Endocr Relat Cancer 24 (6) R239-R259, doi:10.1530/ERC-16-0542 first published on 11 April 2017
    ...somatostatin analogue pasireotide, showing increased binding affinity for SSTR-1, 3 and 5, was compared to octreotide and lanreotide, and has apparently shown superior efficacy in the biochemical control of patients with acromegaly (Colao  et  al. 2014). Pegvisomant, a pegylated analogue of human GH ~~~
  7. Research:
    • Tessa Brabander,
    • Wouter A van der Zwan,
    • Jaap J M Teunissen,
    • Boen L R Kam,
    • Wouter W de Herder,
    • Richard A Feelders,
    • Eric P Krenning,
    • and Dik J Kwekkeboom
    Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate Endocr Relat Cancer 24 (5) 243-251, doi:10.1530/ERC-16-0524 first published on 20 March 2017
    ...somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. Journal of Clinical Oncology 29 2416–2423. (doi:10.1200/JCO.2010.33.7873) Jimenez-Fonseca P, Monleón Getino A, Krug S, Fierro Maya F, Tamagno G, De Herder W, Costa F Jann H & Knowledge Network 2016 A univariate analysis of ~~~
  8. Review:
    • Jenny G Parvani and
    • Mark W Jackson
    Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles Endocr Relat Cancer 24 (4) R81-R97, doi:10.1530/ERC-16-0482 first published on 1 February 2017
    ...somatostatin analogue AN-162 (AEZS-124). Anticancer Drugs 24 150–157. (doi:10.1097/CAD.0b013e32835a7e29) Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al. 2012 The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature ~~~
  9. Commentary:
    • Sylvia L Asa,
    • Walter Kucharczyk,
    • and Shereen Ezzat
    Pituitary acromegaly: not one disease Endocr Relat Cancer 24 (3) C1-C4, doi:10.1530/ERC-16-0496 first published on 25 January 2017
    ...somatostatin analogue treatment in a large series of patients with acromegaly . Clinical Endocrinology 76 96 – 102 . ( doi:10.1111/j.1365-2265.2011.04163.x ) ↵ Hagiwara A , Inoue Y , Wakasa K , Haba T , Tashiro T & Miyamoto T 2003 Comparison of growth hormone-producing and non-growth hormone-pro ~~~
  10. Review:
    • Kjell Öberg and
    • Steven W J Lamberts
    Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future Endocr Relat Cancer 23 (12) R551-R566, doi:10.1530/ERC-16-0151 first published on 3 October 2016
    ...somatostatin analogue with a short-acting formulation of octreotide introduced into clinical practice in the late 1980s. Lanreotide, another somatostatin analogue, became available in the mid-1990s initially as a prolonged-release formulation administered every 10 or 14 days. Long-acting release for ~~~
For checked items

Search Results

Next 10 » New Search

Modify Results

Citation format:
Results / page:
Results order:

This search

  • Alert me when new articles matching this search are published
  • Download all citations on this page to my citation manager

New Articles: issue in progress

  1. December 2017, 24 (12)
  1. Current Issue
  1. Alert me to new issues of Endocrine-Related Cancer

Most